Exploring Endogenous DMT with Rick Strassman, MD

In this episode of the Psychedelic Medicine Podcast, Dr. Evan Cole Lewis joins to explore the topic of psychedelics and seizure disorders. Dr. Lewis is a Canadian Neurologist and holds an appointment as Assistant Professor in the Department of Paediatrics at the University of Toronto. He has special interest in the treatment of neurologic disorders, including functional seizures, with psychedelic therapies. In this conversation, Dr. Lewis shares his expertise on a number of topics at the intersection of psychedelics and seizure disorders. He discusses the neurology behind psychedelics and functional neurological disorders more broadly, explaining why he thinks this is a very promising area of research. He explains that currently very little is known about the topic of psychedelics and seizure disorders, as almost all studies have had epilepsy as an absolute contraindication, leaving researchers with only case reports. However, there are some promising indications in the preclinical data which warrant further investigation. In closing, Dr. Lewis sheds light on potential seizure risks resulting from interactions between psychedelics and other medications.    In this episode you'll hear: The different between epileptic seizures and functional seizures How Dr. Lewis started exploring the topic of psychedelics and functional seizures Why Dr. Lewis thinks psychedelic science has the potential to rebuild bridges between neurology and psychiatry Dr. Lewis’ experiences treating epileptic patients with ketamine The potential for co-administered lithium and psychedelics to cause seizures   Quotes: “I tell people psychedelics are brain network medicine—they kind of dissolve those networks. If the thinking is that FND [Functional Neurological Disorder] is due to dysfunctional connection or hyperconnectivity in certain networks, what we have to do is we have to repair those networks, but first we have to take them apart and build them back up.” [11:03] “Regardless, even if there isn’t even a condition in which psychedelics are utilized in neurology, we need the neurologists to be able to indicate that these patients are safe—or at least do the work and be involved in the clinical team.” [21:05] “Things like drug interactions we pick up with psychedelics again are going to be a big piece of the puzzle that needs to be answered going forward.” [29:17]   Links: Dr. Lewis on LinkedIn Dr. Lewis on YouTube  Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks by Dr. Lewis et al. Case report: Improvement in refractory functional seizures, depression, and quality of life with by Dr. Lewis et al. Psychedelics, epilepsy, and seizures: a review by Dr. Lewis et al. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review by Kelan Thomas, Benjamin Malcolm, et al. ketamine-assisted therapy Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast, Dr. Jenna Valentine joins to explore the intersection of psychedelics and somatic therapy. Dr. Valentine is a doctor of Chinese Medicine who incorporates both functional medicine and somatic experiencing within her practice to help achieve optimal wellness. In this conversation, Dr. Valentine introduces somatic therapy, drawing parallels to psychedelic work and exploring how this modality may support more healthy and holistic psychedelic experiences. She explains how somatic therapy proceeds by tuning into the body, with therapists helping to guide clients’ awareness of the intelligence in their bodies. Dr. Valentine emphasizes the importance of not forcing things in somatic work - with gentler, slower practices often being best to align with health. In closing, she outlines how somatic therapy can be used for preparation and integration of a psychedelic experience, and also explores the possibilities of somatic modalities being used during psychedelic therapy.    In this episode you'll hear: The different forms of somatic therapy The overemphasis on the mind in our culture Why there aren’t contraindications for somatic therapy Somatic therapy as a modality for working with patients diagnosed with biploar disorder or schizophrenia The intersection of healing and re-learning to be playful The importance of “doing less” Why glorifying “heroic doses” of psychedelics can be counterproductive to healing Shadow work and somatic therapy   Quotes: “There’s many different definitions of [somatic therapy] but the one I love the most is: guiding yourself back to your body as your primary resource.” [4:02] “A lot of the work is making sure people learn that they don’t have to feel afraid of themselves—no part of you is ‘coming to get you’ … no part of you is trying to trick you or hurt you or surprise you. Sometimes I’ll describe it as I’m helping people guide themselves back to themselves and find a safe home there again.” [13:05] “We have lost our relationship with discomfort, and a lot of this work is uncomfortable. And the work is being in the discomfort and building a larger capacity for being uncomfortable, and learning the difference between uncomfortable and unhelpful, because that’s not something we’re trained in.” [23:41] “There’s learning that can happen in everything … The expectation is to have no expectation: we can have a loose intention, and then let the body lead.” [47:18]   Links: Dr. Valentine on Instagram Dr. Valentine’s website Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast Tommaso Barba joins to explore the topic of psychedelics for sexual functioning and intimacy. Tommaso is a PhD candidate at the Centre for Psychedelic Research at Imperial College London where his research is focused on understanding the potential role of psychedelic drugs for well-being. Tommaso authored the first paper on the effects of psychedelics on sexual functioning. In this conversation, Tommaso shares results from the multiple studies into psychedelics and sexual functions he has been involved in. He reports that in both a trial comparing psilocybin and escitalopram and a survey of naturalistic psychedelic use, respondents reported positive impacts on sexual functioning following psychedelic experiences. He also speculates about aspects of the psychedelic experience that are interpreted as “erotic” in the midst of the altered state and the reported shifts to experiencing sexual connection as more “spiritual” following psychedelic experiences. In closing, Tommaso discusses the promise of psychedelic journeys for healthy couples and the difficulties of researching this topic since there is no clear pathology being addressed.    In this episode you'll hear: How Tommaso got interested in the intersection of psychedelics and sexual functioning Why SRRIs often have side effects of inhibiting sexual function How psychedelic neuropharmacology may help explain improved sexual functioning following psychedelic experiences The upcoming studies exploring the effects of psychedelic journeys on couples who undergo the experience together The possible differences between MDMA and classic psychedelics in terms of mechanism and impact when it comes to effects on sexual function   Quotes: “When we looked at the positive affect symptoms—like wellbeing, connectedness, ability to feel emotions, and so on… Psilocybin outperformed escitalopram. And given so, we were really curious to investigate further the sex lives of these patients, because an active sex life is a key component of people’s wellbeing, and a very overlooked one.” [7:34] “What we found was that people treated with psilocybin reported improvements in sexual pleasure, in capacity to communicate sexual desires with their partner, in sexual arousal, sexual satisfaction, and similar components of sexual functioning, while people treated with escitalopram did not report any of these changes and tended to report deterioration in this aspect of functioning.” [11:10] “[These psychedelic treatments may] work because it disentangles couples and its capable of individuating the two patients into the context of their relationship so that they start to develop a better identity in the context of the relationship instead of being completely fused into each other and not capable of really developing themselves and communicating their desires and what they want.” [31:15]   Links: Tommaso on Twitter Tommaso on LinkedIn Imperial College Centre for Psychedelic Research online survey study: psychedelics and couples Previous episode: Microdosing and the Placebo Effect with Balázs Szigeti, PhD Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast Kayla Knopp joins to explore the topic of MDMA-Assisted Couples Therapy. Dr. Kayla Knopp is a clinical psychologist and researcher specializing in non-traditional couples and relationships. She specializes in making couple therapies more inclusive, accessible, and effective, including MDMA- and ketamine-assisted couple therapy. In this conversation, Dr. Knopp introduces MDMA-assisted couples therapy, discussing why this entactogen is a good fit for couples therapy. She discusses how MDMA helps couples explore issues by dissolving typical defensive boundaries and encouraging empathy. She emphasizes that not all couples may be a good fit for this therapy, however, and especially cautions against couples therapy in contexts of abuse where connecting with resources for safety and pursuing individual courses of therapy is more appropriate. In closing, Dr. Knopp discusses the importance of screening and the responsibility the psychedelic community has to ensure these substances are being used in safe and effective therapeutic contexts overseen by qualified and caring facilitators.   In this episode you'll hear: The history of MDMA-assisted couples therapy When couple therapy is and is not appropriate Integrating MDMA-assisted therapy with cognitive-behavioral conjoint therapy for PTSD Therapeutic modalities which may be well-suited to MDMA-assisted couples therapy   Quotes: “[MDMA] does so many things that are facilitative of the primary goals of couples therapy, which are to reduce defensiveness, to increase the flexibility that we have in taking our partner’s perspective, increase the empathy and intimacy we feel with other people, increase the reward that we get from positive interpersonal interactions.” [4:33] “When we treat relationship dysfunction, we know mental health often improves as a result of that and conversely, we also know that sometimes when we do mental health treatments, if we ignore the relational context that somebody is living in, we only give them part of what they need in order to fully heal psychiatrically. So, couple-based interventions for mental health disorders, including PTSD, are up-and-coming as a really effective way to address mental health concerns.” [8:14] “MDMA tends to increase our window of tolerance for emotional experiences—it makes it safer and easier for us to remain in contact with feelings that might otherwise feel pretty overwhelming.” [23:48] “I think there’s absolutely a lot of ego and a toxic guru model that can show up in psychedelic-assisted therapy that, as a community, as practitioners, as participants, we need to keep an eye out for and keep ourselves accountable as a community to make sure that we’re not giving folks a pass.” [31:17]   Links: Dr. Knopp on Instagram Enamory website Enamory on Instagram Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics. To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasn’t in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks. Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions. Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional.   In this episode: The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic work   Quotes: “Part of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if you’re always doing that, it ends up having the reverse effect, causing damage.” [12:56] “This is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.” [16:25] “I think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.” [18:39] “When we think about these medications, we should think about combining them with therapy and not just taking these medications as medications… So that’s why with ketamine I’m really recommending it with therapy.” [25:04]   Links: Reconscious Medical Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro. In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents’ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study.   In this episode you'll hear: The early research into ketamine for postpartum depression and whether ketamine remains in breast milk The prevalence of mood concerns in the postpartum population Issues of access with ketamine treatments for new mothers Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice Hormone changes after giving birth and how this might relate to mood concerns Ketamine for postpartum pain   Quotes: “The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it’s not a medicine you have to take every day and it’s not a medicine that’s going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55] “More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22] “That’s what ketamine does so well—it gives people a different view of some of the things they’re really struggling with that they can’t quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they’re usually pretty negative. But the medicine space gives them a different view.” [18:52]   Links: Melissa’s study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites Melissa’s article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression Melissa’s website Deva Collective website  Melissa on Instagram Plant Parenthood website Previous episode: Psychedelics and Women’s Health with Allison Feduccia, PhD Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast, Hannah Raine-Smith and Jocelyn Rose join to discuss the psychedelic assisted EMDR therapy. Hannah is an integrative psychotherapist and independent researcher specializing in psychedelic integration using EMDR therapy. Jocelyn is a research therapist working on psychedelic clinical trials. She also works in private practice, and has a special interest in exploring the unfolding potential of EMDR as a scalable, trauma focused psychedelic assisted therapy. In this conversation, Hannah and Jocelyn introduce the basics of eye movement desensitization and reprocessing (EMDR) therapy and its possible utility in adjunct to psychedelic assisted therapies. They discuss the overlapping mechanisms between EMDR and psychedelic therapies, with both engaging the serotonin 5-HT2 system and promoting neuroplasticity. Hannah and Jocelyn explain their excitement around integrating EMDR with psychedelic therapy, stressing that this may make these treatments more accessible for the patients who could benefit most from psychedelic therapy. In closing, the researchers call for additional investigation of the intersection of psychedelic therapy and EMDR and invite collaboration from anyone else exploring these promising treatments.  You can contact Hannah and Jocelyn at [email protected]   In this episode you'll hear: How EMDR works to help people process traumatic memories Similar neurological effects of psychedelic therapies and EMDR Understanding the adaptive information processing (AIP) framework Hannah and Jocelyn’s novel hypothesis for the basis of hallucinogen persisting perception disorder (HPPD) Using EMDR as an integration therapy for past psychedelic experiences Making psychedelic treatments more accessible and inclusive   Quotes: “Like with indigenous shamanic practices, EMDR uses simple rhythms to alter consciousness. So EMDR is like an ancient healing mechanism that’s been adapted to treat the modern soul.” [4:56] “When we reprocess these memories using bilateral stimulation of the brain, you start thinking and feeling differently about the same events. So trauma therapy isn’t about changing the past, it’s about how you think and feel about those experiences.” [5:26] “Some of the resistance that would normally be present in an EMDR session is diminished when someone has had a recent psychedelic experience.” [12:02] “Research has shown that EMDR taps into the same mechanisms as REM [sleep]. It’s like adding the healing benefits of dreaming whilst on psychedelics but being more in control of what gets reprocessed.” [14:42] “The people who are most likely to have adverse drug reactions to psychedelics—whether that’s HPPD or tolerance—tend to be the people who also have adverse childhood experiences or have traumatic complexity in their biographical content. And so we recognize that there’s a need for trauma-focused psychedelic treatments if we’re going to make these treatments available to the people who need them most and make them scalable—and we think EMDR is a good enough fit for that work to happen.” [25:46]   Links: Hannah and Jocelyn’s article: “Psychedelic-assisted EMDR therapy (PsyA-EMDR): A memory consolidation approach to psychedelic healing” Bridge to the Matrix: A Memory Consolidation Approach to Psychedelic Healing website Hannah on LinkedIn Jocelyn on LinkedIn Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT  Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast, Steven Radowitz, MD joins to discuss the state of the research into ketamine treatments for PTSD. Dr. Steven Radowitz is the Chief Medical Officer and Co-Founder, Nushama. He believes psychedelic medicine’s framework of neuroscience, mystical experience, and integration therapy is the future of mental wellness, and current solutions often fall short, treating symptoms without addressing underlying issues. Dr. Radowitz and the Nushama team have administered thousands of ketamine journeys for mood disorders and are known to be best-in-class and among the most experienced globally. In this conversation, Dr. Radowitz shares the journey of his career in medicine and how he got involved in the treatment of mood disorders with ketamine. He discusses the way he works with patients to determine the best dosing of ketamine for their unique therapeutic needs and the way dosage intersects with the durability of the changes. Dr. Radowitz emphasizes how ketamine promotes neuroplasticity, which allows patients with PTSD to open a critical response window when confronted with triggers and re-code memories of trauma. In closing, Dr. Radowitz discusses the importance of integration and highlights the way psychedelic therapies empower patients to be their own healers.   In this episode you'll hear: Using both psycholytic and psychedelic doses of ketamine and how therapeutic approach differs between the two Stories of transformation from Dr. Radowitz’s ketamine practice The practices Dr. Radowitz recommends for patients following ketamine infusions How Dr. Radowitz uses music in his ketamine practice   Quotes: “As much as we segregate all these mood disorders into separate disease entities… there’s actually a common seed for them all—there’s just different manifestations. But I say about 95% of the people who come in here [for ketamine treatments] have some type of trauma.” [4:56] “The dose doesn’t always correlate with the experience—it usually doesn’t. I can give people the same dose, with the same music, same everything, and they'll have completely different experiences each time.” [13:23] “What we do here is to create a medically safe and an emotionally safe environment for [patients]. But the medicine is them—they’re the therapists in the end. … I want them to realize it’s all coming from them. They have everything they need within themselves to heal.” [32:15]   Links: Nushama website Nushama on LinkedIn Nushama on Instagram Nushama on Facebook Nushama on TikTok Dr. Radowitz on Linkedin The Untethered Soul: The Journey Beyond Yourself by Michael A. Singer Letting Go: The Pathway of Surrender by David R. Hawkins Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook. His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S. In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don’t know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use.    In this episode you'll hear: The overlap between psychedelic experiences and meditation techniques The relationship between fear, self-awareness, and difficult DMT experiences The placebo effect and psychedelic research Dr. Strassman’s thoughts on non-hallucinogenic psychedelics DMT as a possible treatment for strokes to prevent damage and speed recovery Effects of microdosing in animals and humans   Quotes: “I think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. … Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug.” [9:45] “You could still speculate that to the extent that non-drug states resemble those brought on by giving DMT… that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research.” [24:16] “If psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT.” [27:42] “If you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube.” [32:27]   Links: Dr. Strassman’s website The Psychedelic Handbook by Dr. Strassman DMT: The Spirit Molecule by Dr. Strassman DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman Dr. Strassman on FacebookPrevious episode: Exploring DMT Entities with Matthew Johnson, PhD Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast, Stephanie Knatz Peck, PhD joins to discuss the research on psilocybin for anorexia nervosa. Dr. Stephanie Knatz Peck is a clinical psychologist and Associate Clinical Professor at the University of California, San Diego with an expertise in eating disorders. She conducts clinical research on novel treatments for eating disorders and has been involved with clinical research evaluating psychedelics across a variety of mental health indications in the capacity of researcher and therapist. She also published the first ever report on a clinical study evaluating psilocybin for anorexia nervosa.  In this conversation, Dr. Peck discusses the difficulties of treating eating disorders and the emerging evidence around the safety and efficacy of psychedelic-assisted therapies for these conditions. She discusses the results from a study she conducted on the safety and tolerability of psilocybin therapy for females with anorexia nervosa, finding that the treatment was safe and generally well tolerated amongst the trial group. The study additionally found positive treatment outcomes following the psilocybin therapy in a number of participants. In closing, Dr. Peck discusses how psychedelics are able to open a “behavior change window” following dosing sessions—something which may be crucial to their efficacy in treating eating disorders.   In this episode: Dr. Peck’s work treating patients with eating disorders The lesser known diagnostic categories orthorexia and eating disorder not otherwise specified (EDNOS) Genetic predisposition for eating disorders Why the participants in Dr. Peck’s study thought they could benefit from additional psilocybin dosing sessions How transformative psychedelic experiences can help shift values and identities to promote eating disorder recovery   Quotes: “We think that there are specific personality features that predispose someone to engage in dietary restrictive processes or behaviors or actions or modify their lifestyle around exercise and food—and then they fall into anorexia. And the thing that distinguishes those people is that sometimes they have these predisposing factors like a lot of anxiety or preoccupation, an ability to be highly self disciplined… There’s a lot of processes in place that can cause a diet to go awry and turn into anorexia.” [12:29] “Something that distinguishes anorexia from other psychiatric illnesses is that it is an illness that really results in a lot of physiological vulnerability—across all body systems. And so while it might be fine to just assume that with some other psychiatric illnesses we can reliably assume safety, with this particular population there’s cardiac issues, there’s serotonergic things that affect cardiac issues that we really needed some safety data on.”  [19:13] “We really need better treatments [for eating disorders] that treat from the inside out, meaning like what is happening on an underlying psychological level, neuropharmacological level, that’s causing someone to want to engage in these behaviors and I think that is the value of these [psychedelic] treatments is that we are treating from a different direction.” [27:25]   Links: Dr. Peck’s study: Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study Current eating disorder studies at UCSD BrightMind Therapy website Dr. Peck on Twitter Psychedelic Medicine Association Porangui